(GLPG) Galapagos - Ratings and Ratios
Medicine, Oncology, Immunology, CAR-T, Biotech
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 30.8% |
| Value at Risk 5%th | 45.4% |
| Relative Tail Risk | -10.40% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.62 |
| Alpha | 11.25 |
| CAGR/Max DD | -0.14 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.509 |
| Beta | 0.421 |
| Beta Downside | 0.293 |
| Drawdowns 3y | |
|---|---|
| Max DD | 52.73% |
| Mean DD | 30.93% |
| Median DD | 33.08% |
Description: GLPG Galapagos November 10, 2025
Galapagos NV (NASDAQ:GLPG) is a Belgium-based biotech focused on developing small-molecule and cell-therapy candidates for oncology and immunology, primarily targeting the U.S. and European markets.
Its current pipeline includes four point-of-care CAR-T programs: GLPG5101 (CD19 CAR-T for relapsed/refractory non-Hodgkin lymphoma), GLPG5201 (CD19 CAR-T for relapsed/refractory chronic lymphocytic leukemia), GLPG5301 (BCMA CAR-T for relapsed/refractory multiple myeloma), and GLPG3667, which has completed a Phase 1b trial. All CAR-T candidates are in Phase 1/2, indicating early-stage clinical risk but also the potential for rapid value creation if efficacy and safety benchmarks are met.
Strategic collaborations with Gilead Sciences and AbbVie provide non-dilutive funding and development expertise; to date, Galapagos has received over €300 million in upfront and milestone payments, which helps offset its cash burn of roughly €150 million per year (FY 2024). The company’s market capitalization is approximately $7 billion, giving a price-to-cash-burn multiple of about 4.5×, modest relative to the broader CAR-T sector where peers trade at 6–10×.
Key sector drivers that could amplify Galapagos’ upside include the projected CAGR of ~15 % for the global CAR-T market through 2030 and increasing reimbursement willingness for point-of-care manufacturing, which reduces logistics costs and expands access in community hospitals.
For a deeper quantitative assessment, you may want to explore ValueRay’s detailed valuation models for GLPG.
Piotroski VR‑10 (Strict, 0-10) 0.5
| Net Income (-436.0m TTM) > 0 and > 6% of Revenue (6% = 17.2m TTM) |
| FCFTA -0.07 (>2.0%) and ΔFCFTA 1.42pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 1145 % (prev 1338 %; Δ -193.5pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.07 (>3.0%) and CFO -269.4m > Net Income -436.0m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 8.63 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (65.9m) change vs 12m ago -0.08% (target <= -2.0% for YES) |
| Gross Margin -38.90% (prev 56.80%; Δ -95.71pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 6.91% (prev 5.75%; Δ 1.17pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -10.69 (EBITDA TTM -503.2m / Interest Expense TTM 24.4m) >= 6 (WARN >= 3) |
Altman Z'' 3.98
| (A) 0.80 = (Total Current Assets 3.72b - Total Current Liabilities 430.7m) / Total Assets 4.13b |
| (B) -0.16 = Retained Earnings (Balance) -678.8m / Total Assets 4.13b |
| (C) -0.06 = EBIT TTM -260.7m / Avg Total Assets 4.15b |
| (D) -0.27 = Book Value of Equity -340.8m / Total Liabilities 1.25b |
| Total Rating: 3.98 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 37.83
| 1. Piotroski 0.50pt |
| 2. FCF Yield 16.24% |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.00 |
| 5. Debt/Ebitda 0.13 |
| 6. ROIC - WACC (= -16.48)% |
| 7. RoE -15.62% |
| 8. Rev. Trend -12.41% |
| 9. EPS Trend -34.48% |
What is the price of GLPG shares?
Over the past week, the price has changed by +1.76%, over one month by -0.37%, over three months by -0.03% and over the past year by +18.82%.
Is GLPG a buy, sell or hold?
- Strong Buy: 0
- Buy: 0
- Hold: 4
- Sell: 1
- Strong Sell: 1
What are the forecasts/targets for the GLPG price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 27.6 | -14.6% |
| Analysts Target Price | 27.6 | -14.6% |
| ValueRay Target Price | 31.6 | -2.4% |
GLPG Fundamental Data Overview December 10, 2025
P/E Forward = 344.8276
P/S = 7.338
P/B = 0.7307
Beta = -0.05
Revenue TTM = 286.9m EUR
EBIT TTM = -260.7m EUR
EBITDA TTM = -503.2m EUR
Long Term Debt = 7.50m EUR (from capitalLeaseObligations, last quarter)
Short Term Debt = 2.04m EUR (from shortTermDebt, last quarter)
Debt = 8.81m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = -66.9m EUR (from netDebt column, last quarter)
Enterprise Value = -1.77b EUR (1.81b + Debt 8.81m - CCE 3.58b)
Interest Coverage Ratio = -10.69 (Ebit TTM -260.7m / Interest Expense TTM 24.4m)
FCF Yield = 16.24% (FCF TTM -287.0m / Enterprise Value -1.77b)
FCF Margin = -100.0% (FCF TTM -287.0m / Revenue TTM 286.9m)
Net Margin = -151.9% (Net Income TTM -436.0m / Revenue TTM 286.9m)
Gross Margin = -38.90% ((Revenue TTM 286.9m - Cost of Revenue TTM 398.5m) / Revenue TTM)
Gross Margin QoQ = -275.5% (prev 92.79%)
Tobins Q-Ratio = -0.43 (set to none) (Enterprise Value -1.77b / Total Assets 4.13b)
Interest Expense / Debt = 266.8% (Interest Expense 23.5m / Debt 8.81m)
Taxrate = 7.90% (-17.5m / -221.5m)
NOPAT = -240.1m (EBIT -260.7m * (1 - 7.90%)) [loss with tax shield]
Current Ratio = 8.63 (Total Current Assets 3.72b / Total Current Liabilities 430.7m)
Debt / Equity = 0.00 (Debt 8.81m / totalStockholderEquity, last quarter 2.88b)
Debt / EBITDA = 0.13 (negative EBITDA) (Net Debt -66.9m / EBITDA -503.2m)
Debt / FCF = 0.23 (negative FCF - burning cash) (Net Debt -66.9m / FCF TTM -287.0m)
Total Stockholder Equity = 2.79b (last 4 quarters mean from totalStockholderEquity)
RoA = -10.56% (Net Income -436.0m / Total Assets 4.13b)
RoE = -15.62% (Net Income TTM -436.0m / Total Stockholder Equity 2.79b)
RoCE = -9.32% (EBIT -260.7m / Capital Employed (Equity 2.79b + L.T.Debt 7.50m))
RoIC = -8.95% (negative operating profit) (NOPAT -240.1m / Invested Capital 2.68b)
WACC = 7.53% (E(1.81b)/V(1.82b) * Re(7.57%) + (debt cost/tax rate unavailable))
Discount Rate = 7.57% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -33.33 | Cagr: -0.09%
Fair Price DCF = unknown (Cash Flow -287.0m)
EPS Correlation: -34.48 | EPS CAGR: -70.62% | SUE: -1.76 | # QB: 0
Revenue Correlation: -12.41 | Revenue CAGR: -20.34% | SUE: 0.02 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.08 | Chg30d=+0.445 | Revisions Net=+1 | Analysts=1
EPS next Year (2026-12-31): EPS=0.27 | Chg30d=+1.234 | Revisions Net=+1 | Growth EPS=+108.9% | Growth Revenue=-3.2%
Additional Sources for GLPG Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle